Pharming Group N.V.

Share Issue/Capital Change • Apr 17, 2013

PHARMING REDEEMS THIRD TRANCHE OF CONVERTIBLE BOND

Leiden, The Netherlands, April 16, 2013. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that it has redeemed the third tranche of its €16.35 million convertible bond. A total of 26,605,121 shares were issued to the bondholders under the terms and conditions of the bond, serving as a pre-installment for the May 20, 2013 redemption and interest payment.

About the January 2013 Convertible Bonds

As announced in our press release on January 16, 2013, and following the approval of the increase of the Company's authorized share capital during the extraordinary general meeting of shareholders, which was held on February 28, 2013, Pharming will redeem the bond on a month by month basis in seven equal tranches, such that the bond will be redeemed in full on October 01, 2013. Pharming can decide at its discretion to redeem the bond and pay the interest due, by means of monthly equity tranches or cash payments.

As of today, the number of outstanding shares has increased to 168,909,635

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum. RUCONEST® is partnered with Santarus Inc (NASDAQ: SNTS) in North America where the drug has completed Phase III clinical development. The product is also being evaluated for various follow-on indications. Pharming has a unique GMP compliant, validated platform for the production of recombinant human proteins that, with the EU approval of Pharming's rhC1 inhibitor, has proven capable of producing industrial volumes of high quality recombinant human protein in a significantly more economical way through low upfront capital investment and manufacturing costs, compared to current cell based technologies. Pharming now plans to utilise this platform for the development of rhFVIII for the treatment of Haemophilia A. Additional information is available on the Pharming website, www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Sijmen de Vries, CEO: T: +31 71 524 7400

FTI Consulting Julia Phillips/ John Dineen, T: +44 (0)207 269 7193